Guillermo Drelichman
About
Guillermo Drelichman is a scholar working on Physiology, Genetics and Hematology.
According to data from OpenAlex, Guillermo Drelichman has authored 23 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 7 papers in Genetics and 7 papers in Hematology. Recurrent topics in Guillermo Drelichman's work include Lysosomal Storage Disorders Research (11 papers), Iron Metabolism and Disorders (5 papers) and Hemoglobinopathies and Related Disorders (5 papers). Guillermo Drelichman is often cited by papers focused on Lysosomal Storage Disorders Research (11 papers), Iron Metabolism and Disorders (5 papers) and Hemoglobinopathies and Related Disorders (5 papers). Guillermo Drelichman collaborates with scholars based in Argentina, Brazil and United States. Guillermo Drelichman's co-authors include Ana María Martins, Thomas Andrew Burrow, Jennifer Angell, Leorah Ross, Barry E. Rosenbloom, Manisha Balwani, Elena Lukina, Timothy M. Cox, Ana Cristina Puga and Silverio Perrotta and has published in prestigious journals such as The Lancet, Blood and Frontiers in Endocrinology.
In The Last Decade
Guillermo Drelichman
23 papers receiving 402 citations
Peers
Guillermo Drelichman
Koji Arai Japan
Prasanthi Chappa United States
Camila Bononi Almeida Brazil
Pramila Krishnamurthy United Kingdom
Yasuhiro Yamashiro Japan
Ramiro Núñez Spain
Zoya Panahloo United Kingdom
Ayala Abrahamov Israel
Camila Matzenbacher Bittar Brazil
Josiane Bardakdjian‐Michau France
Citations per year, relative to Guillermo Drelichman Guillermo Drelichman (= 1×)
peers
Koji Arai
Countries citing papers authored by Guillermo Drelichman
Since
Specialization
Citations
This map shows the geographic impact of Guillermo Drelichman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillermo Drelichman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillermo Drelichman more than expected).
Fields of papers citing papers by Guillermo Drelichman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Guillermo Drelichman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillermo Drelichman. The network helps show where Guillermo Drelichman may publish in the future.
Co-authorship network of co-authors of Guillermo Drelichman
This figure shows the co-authorship network connecting the top 25 collaborators of Guillermo Drelichman. A scholar is included among the top collaborators of Guillermo Drelichman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillermo Drelichman. Guillermo Drelichman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Caldirola, María Soledad, Paula Carolina Luna, Renata Curciarello, et al.. (2023). Case report: De novo SAMD9L truncation causes neonatal-onset autoinflammatory syndrome which was successfully treated with hematopoietic stem cell transplantation. Frontiers in Pediatrics. 11. 1108207–1108207.
2.
Ropelato, María Gabriela, Marı́a Gabriela Ballerini, María Eugenia Rodríguez, et al.. (2023). Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy. Frontiers in Endocrinology. 14. 1135467–1135467.
3.
Drelichman, Guillermo, Andrea Schenone, James Knight, et al.. (2021). Long-read single molecule real-time (SMRT) sequencing of GBA1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe skeletal phenotypes: Collaborative study from the Argentine Group for Diagnosis and Treatment of Gaucher Disease. Molecular Genetics and Metabolism Reports. 29. 100820–100820.
4.
Drelichman, Guillermo, Gilberto Castañeda‐Hernández, Muhlis Cem Ar, et al.. (2019). The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease. American Journal of Hematology. 95(3). 233–237.
5.
Drelichman, Guillermo, et al.. (2019). Feohifomicosis por Exserohilum rostratum en un paciente pediátrico con leucemia linfoblástica aguda postransplante de médula ósea. Revista Argentina de Microbiología. 52(3). 195–197.
6.
Gatto, Emilia, et al.. (2016). Prodromal Clinical Markers of Parkinson disease in Gaucher Disease Individuals. European Neurology. 76(1-2). 19–21.
7.
Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, et al.. (2015). Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. The Lancet. 385(9985). 2355–2362.
8.
Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, et al.. (2015). ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results. Molecular Genetics and Metabolism. 114(2). S33–S34.
9.
Cox, Timothy M., Guillermo Drelichman, Manisha Balwani, et al.. (2014). ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals. Molecular Genetics and Metabolism. 111(2). S33–S33.
10.
Rosenbloom, Barry E., Timothy M. Cox, Guillermo Drelichman, et al.. (2014). Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results. Blood. 124(21). 1406–1406.
11.
Balwani, Manisha, Timothy M. Cox, Guillermo Drelichman, et al.. (2013). Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals. Blood. 122(21). 3468–3468.
12.
Drelichman, Guillermo, Adriana Linares, Jacobo Villalobos, et al.. (2012). [Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].. PubMed. 72(4). 273–82.
13.
Drelichman, Guillermo, Adriana Linares, Jacobo Villalobos, et al.. (2012). Enfermedad de Gaucher en Latinoamérica: Un informe del Registro Internacional y del Grupo Latinoamericano para la Enfermedad de Gaucher. UNIFESP Institutional Repository (Universidade Federal de São Paulo). 72(4). 273–282.
14.
Lobo, Clarisse, et al.. (2011). Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload – the RELATH study. Hematology. 16(5). 265–273.
15.
Jaimovich, Gregorio, et al.. (2011). Comparison of IV Busulfan and Fludarabine Vs Oral Busulfan Plus Cyclophosphamide As Myeloablative Conditioning Regimens for Acute Leukemias and Myelodisplastic Syndromes. Blood. 118(21). 4575–4575.
16.
Cappellini, Maria Domenica, Mohamed Béjaoui, Leyla Ağaoğlu, et al.. (2011). Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 118(4). 884–893.
17.
Cappellini, Maria Domenica, Silverio Perrotta, Leyla Ağaoğlu, et al.. (2009). Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years.. Blood. 114(22). 4063–4063.
18.
Gattermann, Norbert, N. Zoumbos, Emanuele Angelucci, et al.. (2006). Impact on Iron Removal of Dose Reduction for Non-Progressive Serum Creatinine Increases during Treatment with the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670).. Blood. 108(11). 3824–3824.
19.
Preciado, María Victoria, et al.. (2001). EBV-Associated Hodgkin's Disease in an HIV-Infected Child Presenting with a Hemophagocytic Syndrome. Leukemia & lymphoma. 42(1-2). 231–234.
20.
Svarch, Eva, et al.. (1989). [Progress in the treatment of acute lymphoid leukemia in children. Experience of the GATLA/GLATHEM, 1967-1987].. PubMed. 34(2). 136–43.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Koji Arai Breakdown of academic impact, for papers by Prasanthi Chappa Breakdown of academic impact, for papers by Camila Bononi Almeida Breakdown of academic impact, for papers by Pramila Krishnamurthy Breakdown of academic impact, for papers by Yasuhiro Yamashiro Breakdown of academic impact, for papers by Ramiro Núñez Breakdown of academic impact, for papers by Zoya Panahloo Breakdown of academic impact, for papers by Ayala Abrahamov Breakdown of academic impact, for papers by Camila Matzenbacher Bittar Breakdown of academic impact, for papers by Josiane Bardakdjian‐Michau